There were no statistically significant differences between treatments in the @-day rates of major adverse cardiac or cerebral events ( @ % for bivalirudin , @ % for heparin , and @ % for heparin plus tirofiban , P = @ ) , stent thrombosis ( @ % vs @ % vs @ % , respectively , P = @ ) , acquired thrombocytopenia ( @ % vs @ % vs @ % ; P = @ ) , or in acute ( < @-hour ) stent thrombosis ( @ % in each group ) .